<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study investigates the effect of the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> CRL42796 in a canine model of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Both carotid arteries developed occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> in each of the five control animals (time to occlusion: right carotid artery, 92.6 minutes; left carotid artery, 89.0 minutes) </plain></SENT>
<SENT sid="2" pm="."><plain>A single oral dose of CRL42796 (3 mg/kg) prevented occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> in 4 of 6 vessels and increased time to <z:mp ids='MP_0005048'>thrombosis</z:mp>, albeit not significantly (right carotid artery, 134.1 minutes; left carotid artery, 145.0 minutes) </plain></SENT>
<SENT sid="3" pm="."><plain>When the initial dose of CRL42796 was followed by a second oral dose (3 mg/kg) 2 hours later, 10 of 10 carotid arteries remained patent throughout the period of electrolytic injury </plain></SENT>
<SENT sid="4" pm="."><plain>CRL42796 reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight in both treatment protocols </plain></SENT>
<SENT sid="5" pm="."><plain>Ex vivo platelet aggregation with <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> (AA) or <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>) was reduced at 120, 240, and 360 minutes after two doses of CRL42796 </plain></SENT>
<SENT sid="6" pm="."><plain>A single oral dose reduced <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced responses at 240 and 360 minutes, but significant effects were not observed with AA </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time increased 360 minutes after two oral doses of CRL42796, but not at 120 minutes </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time was unchanged with the single dose of CRL42796 </plain></SENT>
<SENT sid="9" pm="."><plain>The results demonstrate that oral administration of CRL42796 prevents carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> in response to deep vessel wall injury and may have potential value to be characterized in extended preclinical and clinical study </plain></SENT>
</text></document>